findmyKOL
Clinical trialNCT03920228CompletedPhase 2/PHASE3Interventional

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

SponsorPalvella Therapeutics, Inc.Enrollment73Pachyonychia Congenita
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Arizona Research Center

    Phoenix, Arizona, United States

  • Stanford University

    Palo Alto, California, United States

  • Yale University

    New Haven, Connecticut, United States

  • International Dermatology Research

    Miami, Florida, United States

  • Northwestern University

    Chicago, Illinois, United States

  • Minnesota Clinical Study Center

    Fridley, Minnesota, United States

  • Oregon Health and Science University

    Portland, Oregon, United States

  • Paddington Testing Co.

    Philadelphia, Pennsylvania, United States

  • University of Utah

    Murray, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PTX-022Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Apr 2019
Primary completion
19 Sept 2020
Completion
19 Oct 2020
Last update posted
29 Aug 2024
Registered enrollment
73
Registry id
NCT03920228
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.